Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Personalis Inc excels in Q4 earnings, eyes growth through strategic focus

Personalis Inc's Q4 2022 earnings call highlighted strong financial performance, strategic focus on MRD, and guidance for 2023 amidst market challenges and opportunities.
The company's strengths in partnerships, product innovation, and financial management position it well for future growth and success in a competitive landscape.
While facing challenges in sample delivery, margin expectations, and operational changes, Personalis Inc is poised to leverage opportunities in partnerships, product launches, and market expansion.
Navigating the evolving landscape with resilience and adaptability, Personalis Inc aims to drive growth, profitability, and innovation in the coming year.

Personalis Inc reports strong Q1 revenue growth and oncology progress

Personalis Inc's Q1 2023 performance showcased revenue growth and progress in oncology.
The company aims to launch NeXT Personal for clinical use by Q4 2023, targeting cancer diagnostics.
Challenges include managing expenses, net loss, and ensuring efficient cash usage for financial goals.

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences. 29th Annual Credit Suisse Virtual Healthcare Conference Presenting on Tuesday, November 10, 2020 at 4:15 p.m. Eastern Time Oppenheimer Fall MedTech Summit Participating on Thursday, November 12, 2020 About Personalis, Inc. Personalis, Inc. is a growing cancer genomics company trans

Personalis to Participate in Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020

Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Immuno Series US Virtual Meeting

Personalis to Participate in Immuno Series US Virtual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present at IO Combinations 360˚

Personalis, Inc. to Present at IO Combinations 360˚

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Digital World CB & CDx Meeting

Personalis to Participate in Digital World CB & CDx Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Receives Contract Extension and New Task Order from the VA’s Million Veteran Program – Total Awarded to Date Now $175M

Personalis Receives Contract Extension and New Task Order From the VA’s Million Veteran Program – Total Awarded to Date Now $175M

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics

Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics

Personalis: Deep Genomics Leader At A Good Price

Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Personalis (PSNL) Looks Good: Stock Adds 8% in Session

The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.

Personalis Turns to Liquid Biopsies for Growth. Will It Work?

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference

Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference

The genomics company announced a public offering of common stock.

Here's Why Personalis Fell as Much as 13.8% Today

Personalis, Inc. (PSNL) CEO John West on Q2 2020 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis Reports Second Quarter 2020 Financial Results

Personalis Reports Second Quarter 2020 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc.

Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Personalis: Buy This Disruptor In Precision Medicine And Machine Learning

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020

Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Expands Leadership Team with Appointment of Leslie Grab, VP of Intellectual Property & John Lyle, VP of Assay Research and Development

Personalis Further Expands Leadership Team With Appointment of Leslie Grab, VP of Intellectual Property and John Lyle, VP of Assay Research and Development

As of late, it has definitely been a great time to be an investor in Personalis, Inc. (PSNL).

Personalis, Inc. (PSNL) Shares March Higher, Can It Continue?

NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc. ("Personalis" or the "Company") (NASDAQ: PSNL). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL

NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Personalis, Inc. ("Personalis" or "the Company") (NASDAQ: PSNL). Investors who purchased Personalis securities are encouraged to...

PSNL Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Personalis, Inc. and Encourages Investors to Contact the Firm

Personalis, Inc. (PSNL) CEO John West on Q1 2020 Results - Earnings Call Transcript

Personalis: Very Cheap, Promising And Uncertain

Personalis, Inc. (PSNL) CEO John West on Q4 2019 Results - Earnings Call Transcript

News for Personalis Inc Stock (PSNL)